AssetMemo, an evidence-graded drug intelligence terminal

Why it surfaced

Its central promise is unusually concrete: grade the evidence behind every drug asset, including trial design, size, endpoints, and blinding, then publish the rubric and reasoning. The homepage exposes a substantial working dataset—2,560 assets, 1,142 companies, 90,752 registry studies, and a live stream of trial, readout, SEC, and corporate updates.

AssetMemo tracks drug assets, clinical trials, companies, mechanisms, readouts, and related news in a searchable research terminal.